171 related articles for article (PubMed ID: 3516918)
1. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia.
Lambertenghi-Deliliers G; Pogliani E; Maiolo AT; Pacciarini MA; Polli EE
Tumori; 1983 Dec; 69(6):515-9. PubMed ID: 6582678
[TBL] [Abstract][Full Text] [Related]
4. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
5. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses.
Kaplan S; Sessa C; Willems Y; Pacciarini MA; Tamassia V; Cavalli F
Invest New Drugs; 1984; 2(3):281-6. PubMed ID: 6595240
[TBL] [Abstract][Full Text] [Related]
7. 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Cerri R; Risso M; Damasio E; Rossi E
Cancer; 1985 Apr; 55(7):1452-4. PubMed ID: 3856461
[TBL] [Abstract][Full Text] [Related]
8. Antileukemic activity of 4-demethoxydaunorubicin in mice.
Casazza AM; Pratesi G; Giuliani F; Di Marco A
Tumori; 1980 Oct; 66(5):549-64. PubMed ID: 6936969
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
Chisesi T; Capnist G; de Dominicis E; Dini E
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):681-4. PubMed ID: 3164269
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
Carella AM; Berman E; Maraone MP; Ganzina F
Haematologica; 1990; 75(2):159-69. PubMed ID: 2192943
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.
Gillies HC; Herriott D; Liang R; Ohashi K; Rogers HJ; Harper PG
Br J Clin Pharmacol; 1987 Mar; 23(3):303-10. PubMed ID: 3471265
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
[TBL] [Abstract][Full Text] [Related]
13. Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.
Eridani S; Slater NG; Singh AK; Pearson TC
Blut; 1985 Jun; 50(6):369-72. PubMed ID: 3859341
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
15. Preliminary observations on intravenous idarubicin (4-demethoxydaunorubicin) in the chronic and accelerated phase of chronic myelogenous leukemia.
Battista R; D'Emilio A; Vespignani M; Pacciarini MA; Dini E
Tumori; 1986 Aug; 72(4):389-93. PubMed ID: 3464125
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
Kavanagh JJ; Yeung KY; Savaraj N; Krakoff IH
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1187-9. PubMed ID: 3865774
[TBL] [Abstract][Full Text] [Related]
17. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Stuart NS; Cullen MH; Priestman TJ; Blackledge GR; Tyrrell CJ
Cancer Chemother Pharmacol; 1988; 21(4):351-4. PubMed ID: 3163529
[TBL] [Abstract][Full Text] [Related]
19. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
20. Oral idarubicin in adult acute leukemia: a preliminary experience.
Lambertenghi-Deliliers G; Pogliani E; Annaloro C; Pacciarini MA; Polli EE
Tumori; 1986 Apr; 72(2):157-61. PubMed ID: 3458337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
